Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 1/20 | 0.44 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.39 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18860312 | 0.92 | DDB1 (0.46) | DDB1CRBNHDAC1HTTNPC1 | |
| SCHEMBL18838408 | 0.92 | DDB1 (0.46) | DDB1CRBNHDAC1HTTNPC1 | |
| SCHEMBL18838296 | 0.84 | EZH2 (0.45) | DDB1CRBNHDAC1NPC1RAB9A | |
| SCHEMBL20400066 | 0.79 | EPHX1 (0.34) | KMT2ASSTR4 | |
| SCHEMBL21828958 | 0.79 | EPHX1 (0.34) | KMT2ASSTR4 | |
| SCHEMBL19995756 | 0.77 | ALDH1A1 (0.49) | MEN1KMT2AALDH1A1 | |
| SCHEMBL18860275 | 0.77 | DRD4 (0.54) | HDAC1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL18860279 | 0.76 | CARM1 (0.46) | MEN1KMT2A | |
| SCHEMBL18860282 | 0.75 | HTR2A (0.54) | HDAC1MEN1KMT2A | |
| SCHEMBL18838432 | 0.75 | CYP2D6 (0.43) | MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3340988-B1 | ION CHANNEL INHIBITORY COMPOUNDS, PHARMACEUTICAL FORMULATIONS AND USES | AFASCI INC (US) | 2025-04-09 | — | — | EP | disclosed |
| CN-108289886-B | Ion channel inhibiting compounds, pharmaceutical formulations and uses | 安华赛公司 | 2022-01-28 | — | — | CN | disclosed |
| US-10562857-B2 | Ion channel inhibitory compounds, pharmaceutical formulations, and uses | AFASCI, INC. (US) | 2020-02-18 | — | — | US | disclosed |
| US-10562857-B2 | Ion channel inhibitory compounds, pharmaceutical formulations, and uses | AFASCI, INC. (US) | 2020-02-18 | — | — | US | disclosed |
| US-20180312471-A1 | Ion Channel Inhibitory Compounds, Pharmaceutical Formulations, and Uses | AFASCI, INC. (US) | 2018-11-01 | — | — | US | disclosed |
| EP-3340988-A1 | ION CHANNEL INHIBITORY COMPOUNDS, PHARMACEUTICAL FORMULATIONS AND USES | Afasci, Inc. (US) | 2018-07-04 | — | — | EP | disclosed |
| WO-2017083867-A1 | ION CHANNEL INHIBITORY COMPOUNDS, PHARMACEUTICAL FORMULATIONS AND USES | AFASCI, INC. (US) | 2017-05-18 | — | — | WO | disclosed |
| WO-2017083867-A1 | ION CHANNEL INHIBITORY COMPOUNDS, PHARMACEUTICAL FORMULATIONS AND USES | AFASCI, INC. (US) | 2017-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10562857-B2 | Ion channel inhibitory compounds, pharmaceutical formulations, and uses | CACNA1I, CACNA1G, CACNA1H | DDB1 4782/4885CRBN 3976/4885HDAC1 1735/4885 |
| US-20180312471-A1 | Ion Channel Inhibitory Compounds, Pharmaceutical Formulations, and Uses | CACNA1I, CACNA1G, CACNA1H | DDB1 4782/4885CRBN 3976/4885HDAC1 1735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.